About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
Previous Close | $45.80 | Open | $46.42 |
Volume | 2.68M | Market Cap | 117.361B |
Yield | 3.65 % | Last Dividend | $1.70 |
Amgen, AstraZeneca speed toward filing n... | 9:00 AM |
On the hunt for a novel competitor to Sanofi and Regeneron's Dupixent in severe asthma, Amgen and AstraZeneca posted |
Oral Contraceptive Pills Market Share, G... | 5:56 AM |
New year, new updates! Our reports have been revised for market size, forecasts, and strategies to take on 2021 after the COVID-19 impact: https://www... |
Antacid Market With Top Players like Bay... | 2:39 AM |
An off-the-shelf report on Antacid Market which has been compiled after an in-depth analysis of the market trends prevailing across five geographies (... |
Chlorpheniramine Maleate Market Overview... | 02/25/21 |
Allied Market Research (USA, Oregon, Portland) Published Latest Report titled, ???Chlorpheniramine Maleate Market: Global Opportunity Analysis and Ind... |
Cold Pain Therapy Market worth $2.0 bill... | 02/25/21 |
CHICAGO , Feb. 25, 2021 /PRNewswire/ -- According to the new market research report " Cold Pain Therapy Market by Product (OTC (Gels, Creams, Patches,... |
Hospital Pharmaceuticals Market - Bayer ... | 02/25/21 |
Hospital Pharmaceuticals Market Report 2020 added recently by CMI, evaluates the industry in terms of market size, market share, revenue estimation, a... |
Diabetes Management Market Demand And Fu... | 02/24/21 |
Diabetes Management Market Overview: The market research report on the Global Diabetes Management Market offered by Straits Research, analyses the maj... |
Weak Q3 show, margin pressures to keep S... | 02/24/21 |
Read more about Weak Q3 show, margin pressures to keep Sanofi stock under pressure on Business Standard. Growth led by power brands and new launches c... |
SIRION Biotech Announces Collaboration w... | 02/23/21 |
MUNICH--(BUSINESS WIRE)-- #AAV--SIRION Biotech announced that it signed a license and collaboration agreement with Sanofi. |
FDA Approves Regeneron/Sanofi's Libtayo ... | 02/23/21 |
The FDA approved expanded use of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi???s SA (NASDAQ: SNY) immunotherapy Libtayo (cemiplimab-rwlc) ... |
Global Facial Injectable Market (2020 to... | 02/23/21 |
DUBLIN--(BUSINESS WIRE)--The "Facial Injectable Market - Forecasts from 2020 to 2025" report has been added to ResearchAndMarkets.com's offering. The ... |
GSK, Sanofi start new COVID-19 vaccine s... | 02/22/21 |
GlaxoSmithKline and Sanofi on Monday announced the start of a new Phase 2 trial involving their protein-based COVID-19 vaccine candidate after facing ... |
United States Diabetes Drug Market Repor... | 02/22/21 |
DUBLIN--(BUSINESS WIRE)--The "US Diabetes Drug Market, Dosage, Price, Sales Insight 2021 - 2026" report has been added to ResearchAndMarkets.com's off... |
Sanofi producing Johnson & Johnson COVID... | 02/22/21 |
French drug maker Sanofi, battling development delays with its own vaccine candidates against COVID-19, is turning over more of its vaccine production... |
GSK, Sanofi restart testing for COVID-19... | 02/22/21 |
Pharma companies GlaxoSmithKline and Sanofi announced Monday that they have begun a second-stage clinical trial for their protein-based COVID-19 vacci... |
Sanofi to help second rival produce COVI... | 02/22/21 |
French drug maker Sanofi is going to produce as many as 12 million coronavirus vaccine doses per month for rival Johnson & Johnson |
STAT+: Pharmalittle: Glaxo and Sanofi st... | 02/22/21 |
GlaxoSmithKline and Sanofi have started a new clinical trial of their Covid-19 vaccine candidate, reviving their efforts against the pandemic after a ... |
Sanofi, GSK Announce Phase 2 of Enhanced... | 02/22/21 |
No summary available. |
Anti-PCSK9 Monoclonal Antibody Market Re... | 02/22/21 |
Los Angeles, United State, February 2021, ??? ??? QY Research offers an overarching research and analysis-based study on the global Anti-PCSK9 Monoclo... |
Sanofi, GlaxoSmithKline start new COVID-... | 02/22/21 |
The drugmakers pushed back the rollout of their experimental COVID-19 shot in December because a study found it generated an "insufficient" immune res... |
Date | 2021-02-05 (BMO) | Est. (EPS/Rev.) | $0.69/ 11.39B |
Actual (EPS/Rev.) | $1.45/ $11.19 B | EPS (TTM) | 1.3 |
Total Revenue | $1.3B | Total Liabilities | $2.1B |
Cost of Revenue | $2.5B | Total cash flow | $3.2 |
Total Assets | $29.98B |
% Insider | 12.52% | % Institutional | 76.43% |
Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Service Name | Trader | % Success | |
---|---|---|---|
Kiplinger - JAMES K. GLASSMAN | StockHoot | 70.00 % | Follow |
1035even | Evan Earle | 61.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.